Michael McCleerey

Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA.

Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA.

Endo Health Solutions, Inc. operates as holding company with interest in providing health care services. It offers pain management, pelvic health, urology, endocrinology and oncology services. The company was founded by Carol A. Ammon on November 18, 1997 and is headquartered in Malvern, PA.

Medco Health Solutions, Inc. retails drugs, pharmaceuticals and other health products through online. The firm provides pharmacy services which are designed for private and public employers, health plans, labor unions government agencies of all sizes and individuals. The company was founded in June 1983 and is headquartered in Franklin Lakes, NJ.

AcuFocus, Inc. develops KAMRA inlay for the treatment of presbyopia. Its KAMRA inlay is an intra-corneal inlay designed to create a small aperture effect, allowing the eye to see near and intermediate objects more clearly. The company was founded in 2001 and is headquartered in Irvine, CA.

Lantheus Medical Imaging, Inc. engages in the manufacture, marketing, sale, and distribution of medical imaging products. It provides diagnostic imaging and nuclear medicine products that assist clinicians with the detection of disease, primarily cardiovascular. Its product protfolio includes DEFINITY, TechneLite, Xenon, AZEDRA, Cardiolite, and NEUROLITE. The company was founded in 1956 and is headquartered in North Billerica, MA.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

LensGen, Inc. develops an accommodating intraocular lens based solution to treat presbyopia and cataracts. It focuses on restoring youthful vision to millions of cataract and presbyopia patients with a new classification of fluid-optic intraocular lenses. The company was founded by Ramgopal Rao on April 23, 2013 and is headquartered in Irvine, CA.

Alcon Laboratories, Inc. develops and manufactures ophthalmic pharmaceutical products. The firm offers over-the-counter eye care products, medical devices, equipment, ophthalmic drugs, surgical instruments, needles, and sutures for microsurgery and disposable drapes. The company was founded by Robert Alexander and William Conner in 1945 and is headquartered in Fort Worth, TX.

The University of St. Thomas is an institution that values diversity, equity, and inclusion. The private company is based in St. Paul, MN. It offers over 150 undergraduate majors and minors, as well as graduate programs in various fields such as business, engineering, law, education, social work, and arts and humanities. The University of St. Thomas was founded in 1885 by John Ireland.

Life Sciences Pennsylvania (LSPA) is a trade association that represents various entities in the life sciences industry, including biotechnology, medical device, diagnostic, pharmaceutical, research, and investment companies, as well as service providers. The non-profit company is based in Wayne, PA and has subsidiaries in the United States. The organization unifies innovators in the state to make Pennsylvania a leader in the life sciences industry. Founded in 1989, LSPA aims to create a business and public policy environment that encourages and incentivizes the diverse life sciences economy in Pennsylvania. Christopher P. Molineaux has been the CEO of the company since 2009.

Healthcare Royalty Management LLC (Healthcare Royalty) is a private equity subsidiary of Cowen, Inc. founded in 2007 by Gregory Brown. The firm is headquartered in Stamford, Connecticut.

KeraLink International, Inc. operates as a non-governmental network of eye and tissue banks. It also provides ocular tissues used in transplant surgeries. The company was founded in 1962 and is headquartered in Baltimore, MD.

New England Healthcare Institute operates as a national nonprofit, nonpartisan organization composed of stakeholders from across all key sectors of health and health care. The company was founded by Henri A. Termeer in 2002 and is headquartered in Boston, MA.

American Academy of Ophthalmology, Inc. is the world's largest association of eye physicians and surgeons. The non-profit company is based in San Francisco, CA, and has subsidiaries in the United States. The company advocates for patients and the public and set standards for ophthalmic education. The organization provides information about managing a practice, clinical pearls, and how to thrive in residency for young ophthalmologists. The company also offers an Outstanding Humanitarian Service Award and have committees that are essential to the establishment and implementation of the organization's mission and strategic goals. The Academy's website, EyeSmart, provides information on eye diseases, treatments, news, and tips for lifelong eye health. The company also has a faculty development program for their annual meeting and offer a program called Eyecelerator that advances eye care innovation by connecting creative entrepreneurs with mission-driven investors and access to markets.

Xellia Pharmaceuticals AS develops, manufactures, and supplies pharmaceutical drugs. The firm engages in the filed of biotechnology, synthetic organic chemistry development, and analytical development. The company was founded in 1946 and is headquartered in Oslo, Norway.

Xellia Pharmaceuticals ApS manufactures pharmaceutical products. Its products include pharmaceutical ingredients, finished dosage forms and novel anti infective pipeline. The company was founded in 1959 and is headquartered in Copenhagen, Denmark.

Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019.

New Xellia Group A/S operates as an investment holding Danish company. The private company is based in Copenhagen, Denmark.

Mynosys Cellular Devices, Inc. develops micro-surgical technology. The company was founded by Christopher Keller and David Sretavan and is headquartered in Fremont, CA.

Iantrek Inc provides biotechnology services. The company is headquartered in White Plains, NY.

InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy.